

process, etc.). The records required by § 179.25(e) are used by FDA inspectors to assess compliance with the regulation that establishes limits within which radiation may be safely used to treat food. The agency cannot ensure safe use without a method to assess compliance

with the dose limits, and there are no practicable methods for analyzing most foods to determine whether they have been treated with ionizing radiation and are within the limitations set forth in part 179. Records inspection is the only way to determine whether firms are

complying with the regulations for treatment of foods with ionizing radiation

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN¹

| 21 CFR Section | No. of Recordkeepers | Annual Frequency of Recordkeeping | Total Annual Records | Hours per Recordkeeper | Total Hours |
|----------------|----------------------|-----------------------------------|----------------------|------------------------|-------------|
| 179.25(e) | 6 | 120 | 720 | 1 | 720 |

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

The number of firms who process food using irradiation is extremely limited. FDA estimates that there are two irradiation plants whose business is devoted primarily (i.e., approximately 100 percent) to irradiation of food and other agricultural products. Four other firms also irradiate small quantities of food. FDA estimates that this irradiation accounts for no more than 10 percent of the business for each of these firms. Therefore, the average estimated burden is based on: Two facilities devoting 100 percent of their business (or 600 hours for recordkeeping annually) to food irradiation; four facilities devoting 10 percent of their business or 120 hours (4 x 30 hours) for recordkeeping annually to food irradiation.

No burden has been estimated for the labeling requirements in §§ 179.21(b)(2)(i) and (b)(2)(ii) and 179.26(c) because the information to be disclosed is information that has been supplied by FDA. Under 5 CFR 1320.3(c)(2), the public disclosure of information originally supplied by the Federal Government to the recipient for the purpose of disclosure to the public is not a collection of information.

Dated: December 19, 2002.

Margaret M. Dotzel,

Assistant Commissioner for Policy.

[FR Doc. 02-32662 Filed 12-26-02; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 02N-0516]

Agency Information Collection Activities; Proposed Collection; Comment Request; Request for Samples and Protocols

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions relating to the regulations which state that protocols for samples of biological products must be submitted to the agency.

DATES: Submit written or electronic comments on the collection of information by February 25, 2003.

ADDRESSES: Submit electronic comments on the collection of information to <http://www.accessdata.fda.gov/scripts/oc/dockets/edockethome.cfm>. Submit written comments on the collection of information to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: JonnaLynn P. Capezzuto, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B-26, Rockville, MD 20857, 301-827-4659.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests

or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques when appropriate, and other forms of information technology.

Request for Samples and Protocols (OMB Control Number 0910-0206)—Extension

Under section 351 of the Public Health Service Act (the PHS Act) (42 U.S.C. 262), FDA has the responsibility to issue regulations that prescribe standards designed to ensure the safety, purity, and potency of biological products and to ensure that licenses for such products are only issued when a product meets the prescribed standards. Under § 610.2 (21 CFR 610.2), FDA may at any time require manufacturers of licensed biological products to submit to FDA samples of any lot along with the protocols showing the results of

applicable tests before marketing the lot of the product. In addition to § 610.2, there are other regulations that require the submission of samples and protocols for specific licensed biological products: § 660.6 (21 CFR 660.6) (Antibody to Hepatitis B Surface Antigen), § 660.36 (21 CFR 660.36) (Reagent Red Blood Cells), and § 660.46 (21 CFR 660.46) (Hepatitis B Surface Antigen).

Section 660.6(a) provides requirements for the frequency of submission of samples from each lot of Antibody to Hepatitis B Surface Antigen product, and § 660.6(b) provides the requirements for the submission of a protocol containing specific information along with each required sample. For § 660.6 products subject to official release by FDA, one sample from each filling of each lot is required to be submitted along with a protocol consisting of a summary of the history or manufacture of the product, including all results of each test for which test results are requested by the Center for Biologics Evaluation and Research (CBER). After official release is no longer required, one sample along with a protocol is required to be submitted at an interval of 90 days. In addition, samples, which must be accompanied by a protocol, may at any time be required to be submitted to FDA if continued evaluation is deemed necessary.

Section 660.36(a) requires, after each routine establishment inspection by FDA, the submission of samples from a lot of final Reagent Red Blood Cell product along with a protocol containing specific information. Section 660.36(a)(2) requires a protocol contain information including, but not limited to, manufacturing records, test records, and test results. Section 660.36(b) requires a copy of the antigenic constitution matrix specifying the antigens present or absent to be

submitted to FDA at the time of initial distribution of each lot.

Section 660.46(a) provides requirements for the frequency of submission of samples from each lot of Hepatitis B Surface Antigen product, and § 660.46(b) provides the requirements for the submission of a protocol containing specific information along with each required sample. For § 660.46 products subject to official release by FDA, one sample from each filling of each lot is required to be submitted along with a protocol consisting of a summary of the history or manufacture of the product, including all results of each test for which test results are requested by CBER. After notification of official release is received, one sample along with a protocol is required to be submitted at an interval of 90 days. In addition, samples, which must be accompanied by a protocol, may at any time be required to be submitted to FDA if continued evaluation is deemed necessary.

Samples and protocols are required by FDA to help ensure the safety, purity, or potency of the product because of the potential lot-to-lot variability of a product produced from living organisms. In cases of certain biological products (e.g., Albumin, Plasma Protein Fraction, and specified biotechnology and specified synthetic biological products) that are known to have lot-to-lot consistency, official lot release is not normally required. However, submissions of samples and protocols of these products may still be required for surveillance, licensing, and export purposes, or in the event that FDA obtains information that the manufacturing process may not result in consistent quality of the product.

The following burden estimate is for protocols required to be submitted with each sample. The collection of samples is not a collection of information under

5 CFR 1320.3(h)(2). Respondents to the collection of information under § 610.2 are manufacturers of any licensed biological product. Respondents to the collection of information under §§ 660.6(b), 660.36(a)(2) and (b), and 660.46(b) are manufacturers of the specific products referenced above. The estimated number of respondents for each regulation is based on the annual number of manufacturers that submitted samples and protocols for biological products including submissions for lot release, surveillance, licensing, or export. There are an estimated 329 manufacturers of licensed biological products, however, based on information obtained from FDA's database system, approximately 83 manufacturers submitted samples and protocols in fiscal year 1999 and 2000, under the regulations cited previously. FDA estimates that approximately 76 manufacturers submitted protocols under § 610.2 and 7 manufacturers submitted protocols under the regulations for the specific products.

The total annual responses are based on the annual average of FDA's final actions completed in fiscal year 1999 and 2000, which totaled 6,747, for the various submission requirements of samples and protocols for biological products. The rate of final actions is not expected to change significantly in the next few years. The hours per response are based on information provided by industry. The burden estimates provided by industry ranged from 1 to 5.5 hours. Under § 610.2, the hours per response are based on the average of these estimates and rounded to 3 hours. Under the remaining regulations, the hours per response are based on the higher end of the estimate (rounded to 5 or 6 hours) because more information is generally required to be submitted in the protocol than under § 610.2. FDA estimates the burden of this information collection as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN¹

| 21 CFR Section | No. of Respondents | Annual Frequency per Response | Total Annual Response | Hours per Response | Total Hours |
|----------------------|--------------------|-------------------------------|-----------------------|--------------------|-------------|
| 610.2 | 76 | 86.5 | 6,574 | 3 | 19,722 |
| 660.6(b) | 4 | 28.5 | 114 | 5 | 570 |
| 660.36(a)(2) and (b) | 1 | 1 | 1 | 6 | 6 |
| 660.46(b) | 2 | 29 | 58 | 5 | 290 |
| Total | 83 | | 6,747 | | 20,588 |

¹ There are no capital costs or operating and maintenance costs associated with this collection.

Dated: December 19, 2002.

Margaret M. Dotzel,

Assistant Commissioner for Policy.

[FR Doc. 02-32749 Filed 12-26-02; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4730-N-52]

Federal Property Suitable as Facilities To Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

EFFECTIVE DATE: December 27, 2002.

FOR FURTHER INFORMATION CONTACT:

Mark Johnston, Department of Housing and Urban Development, Room 7262, 451 Seventh Street SW., Washington, DC 20410; telephone (202) 708-1234; TTY number for the hearing- and speech-impaired (202) 708-2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588.

SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in *National Coalition for the Homeless v. Veterans Administration*, No. 88-2503-OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless. Today's Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week.

Dated: December 19, 2002.

John D. Garrity,

Director, Office of Special Needs, Assistance Programs.

[FR Doc. 02-32438 Filed 12-26-02; 8:45 am]

BILLING CODE 4210-29-M

DEPARTMENT OF THE INTERIOR

Office of the Secretary

Consultation Meetings on the Department of the Interior's Financial Assistance Programs

AGENCY: Office of the Secretary, Interior.

ACTION: Notice of public regional consultation meetings on the Federal Financial Assistance Management Improvement Act of 1999 (Public Law 106-107).

SUMMARY: The Department of the Interior is conducting several regional consultation meetings to implement the Federal Financial Assistance Management Improvement Act of 1999. The meetings are designed to give interested members of the public a chance to comment on the Department's financial assistance programs and offer suggestions for changes. We encourage any interested individuals or organizations to participate by attending the consultations or by providing written comments. We are especially interested in comments by current financial assistance recipients and applicants.

DATES: See the **SUPPLEMENTARY INFORMATION** section for dates of meetings.

ADDRESSES: Meetings will be held in San Diego, California; Albuquerque, New Mexico; Honolulu, Hawaii; and Washington, DC. See the **SUPPLEMENTARY INFORMATION** section for the locations of the meetings.

FOR FURTHER INFORMATION CONTACT:

Tammy Pataluna, telephone: 202-208-4080, e-mail: tammy_pataluna@ios.doi.gov, mailing address: 1849 C Street, NW., Mail Stop 5512, Washington, DC 20240, website: <http://www.doi.gov/pam/Grantcomment.html>.

SUPPLEMENTARY INFORMATION: The Department is conducting regional consultation meetings to discuss the Federal Financial Assistance Management Improvement Act of 1999 (Public Law 106-107) (the "Act"). The Act requires federal agencies to improve the effectiveness and performance of federal financial assistance programs; simplify federal financial assistance application and reporting requirements; improve the delivery of services to the public; and facilitate greater coordination among those responsible

for delivering such services. The Act requires agencies to receive comments from the public and to consult with representatives of non-Federal entities regarding the development of a plan to simplify their financial assistance programs. The Department has already participated in a government-wide consultation and is now seeking information specific to Interior's programs. At these meetings, the Department will explain its financial assistance programs and application requirements and solicit suggestions for improvements that it can make. If you or an organization that you represent has an interest in the Department's financial assistance programs, we encourage you to attend these meetings and participate in the consultation process.

The following bureaus and offices of the Department are sponsoring the consultation meetings: The Bureau of Indian Affairs, the Bureau of Land Management, Bureau of Reclamation, the Minerals Management Service, the National Business Center, the National Park Service, the Office of Acquisition and Property Management, the Office of the Assistant Secretary for Policy Management and Budget, the Office of Insular Affairs, the Office of Surface Mining, the U.S. Fish and Wildlife Service, and the U.S. Geological Survey. The meeting in Honolulu is specifically geared toward organizations and individuals interested in obtaining, and authorized to obtain, financial assistance from the Department's Office of Insular Affairs. The second consultation scheduled in Albuquerque, NM, (February 5, 2003, 1 p.m.) is specifically for organizations, individuals and Tribes interested in obtaining further information on the Bureau of Indian Affairs' grants and financial assistance process. The following table shows the dates and times of the regional meetings. For the convenience of those who require accommodations, we have reserved hotel rooms at a special reduced rate at each meeting location. To obtain the special rate, contact the hotel following the instructions given in the table. Be sure to mention that you want the special rate for Consultation Under Public Law 106-107. For further information, contact Tammy Pataluna at the number or address shown in the **FOR FURTHER INFORMATION CONTACT** section.